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The glycosphingolipid isoglobotrihexosylceramide, or isogloboside 3 (iGb3), is believed to be critical for natural killer T
(NKT) cell development and self-recognition in mice and humans. Furthermore, iGb3 may represent an important
obstacle in xenotransplantation, in which this lipid represents the only other form of the major xenoepitope
Gala(1,3)Gal. The role of iGb3 in NKT cell development is controversial, particularly with one study that suggested that
NKT cell development is normal in mice that were rendered deficient for the enzyme iGb3 synthase (iGb3S). We
demonstrate that spliced iGb3S mRNA was not detected after extensive analysis of human tissues, and furthermore,
the iGb3S gene contains several mutations that render this product nonfunctional. We directly tested the potential
functional activity of human iGb3S by expressing chimeric molecules containing the catalytic domain of human iGb3S.
These hybrid molecules were unable to synthesize iGb3, due to at least one amino acid substitution. We also
demonstrate that purified normal human anti-Gal immunoglobulin G can bind iGb3 lipid and mediate complement
lysis of transfected human cells expressing iGb3. Collectively, our data suggest that iGb3S is not expressed in humans,
and even if it were expressed, this enzyme would be inactive. Consequently, iGb3 is unlikely to represent a primary
natural ligand for NKT cells in humans. Furthermore, the absence of iGb3 in humans implies that it is another source of
foreign Gala(1,3)Gal xenoantigen, with obvious significance in the field of xenotransplantation.
Citation: Christiansen D, Milland J, Mouhtouris E, Vaughan H, Pellicci DG, et al. (2008) Humans lack iGb3 due to the absence of functional iGb3-synthase: Implications for NKT
cell development and transplantation. PLoS Biol 6(7): e172. doi:10.1371/journal.pbio.0060172
Introduction
Identiﬁcation of endogenous antigens that regulate NKT
cell development and self-recognition represents a major goal
in immunology. This unique population of T cells is
characterised by expression of an invariant Va14Ja18
TCR—Va24Ja18 in humans—and the recognition of glyco-
lipid antigens presented by CD1d [1]. When activated, natural
killer T (NKT) cells regulate immune responses through their
ability to produce large amounts of cytokines such as
interferon (IFN)-c and interleukin (IL)-4 [2]. NKT cell
deﬁciencies are associated with a range of diseases, including
cancer, autoimmunity, and infection, in mice and humans [2].
This, combined with the fact that NKT cell numbers vary
widely in humans [3], highlights the importance of under-
standing the endogenous antigens in humans that regulate
NKT cell development and function.
Initial work demonstrated that a-galactosylceramide (a-
GalCer), a glycosphingolipid originally derived from a marine
sponge [4], was a potent agonist for NKT cells in a CD1d-
dependent manner in both mice and humans [5,6]. However,
the physiological relevance of this in mammalian systems was
difﬁcult to understand because a-GalCer is not a mammalian
product. Zhou et al. [7] demonstrated that a deﬁciency in the
lysosomal enzymes b-hexaminidase A and B selectively
abrogated NKT cell development, suggesting that glycoli-
pid(s) downstream of these enzymes are responsible for NKT
cell selection. Experiments to directly test which of the
candidate glycolipids were capable of stimulating NKT cells
pointed to the glycosphingolipid, isogloboside 3 (iGb3). Both
mouse and human fresh NKT cells, and NKT cell hybridomas
and lines, responded to iGb3, and furthermore, speciﬁc
inhibition of iGb3 on human cells, using isolectin B4 (IB4)
that should selectively target iGb3 via its terminal
Gala(1,3)Gal sugars, suggested that iGb3 was also a primary
human self-antigen for NKT cells [7]. These data led the
authors to suggest that iGb3 was the main endogenous ligand
responsible for NKT cell development and self-recognition in
both mice and humans. Subsequent studies from independ-
ent groups have conﬁrmed that iGb3 is an agonist ligand for
at least a subset of mouse and human NKT cells [8–13], and
furthermore, that this glycosphingolipid appears to be
important for shaping the NKT cell TCR repertoire in mice
[12]. However, recent studies have challenged the hypothesis
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PLoS BIOLOGYthat iGb3 is the primary ligand responsible for NKT cell
development in mice [14–16]. One of these studies [16] failed
to detect iGb3 in mouse or human thymus, although this
study could not exclude the existence of low levels of iGb3, or
higher levels of iGb3 expressed by a minor subset of the
thymus. Another study [15] demonstrated, by using iGb3
synthase (iGb3S) knockout mice, that NKT cell development
was apparently normal, which more strongly suggested that
iGb3 is at least not essential for this process in mice. Lastly,
two papers have provided evidence that the defect in NKT
cell development in Hex-b–deﬁcient mice may be the
lysosomal storage disease that occurs with this mutation, thus
causing a nonspeciﬁc defect in glycolipid processing and
presentation [14,17,18]. The ability of iGb3 to activate human
NKT cells is not in dispute; what remains in question is the
role of iGb3 in human NKT cell biology.
Another issue of major importance involving iGb3 is from
the perspective of xenotransplantation, in which expression
of this glycolipid on the cell surface of pig tissue could
represent a major problem if it is not present in humans.
iGb3 is synthesized by iGb3S, a member of the a1,3Gal/
GalNAc transferase or Family 6 glycosyltransferases. Other
family members include a1,3galactosyltransferase (a1,3 GT),
and the B blood group transferase, which like iGb3S, transfer
aGal. In contrast, the two other members of the family, A
blood group transferase and Forssman synthetase, transfer
aGalNAc. Members of Family 6 are the only known
mammalian glycosyltransferases that transfer either aGal or
aGalNAc in an a1,3 linkage to their respective acceptor
molecules. Analysis of the human genome shows the genes for
the a1,3GT, iGb3S, A/B blood group transferase, and the
Forssman synthetase are present [19]. Recently, GT6m7, a new
Family 6 member, was reported [19]; however, in humans, the
gene for this glycosyltransferase contains a premature stop
codon in the last exon. Indeed, mutation appears to be
common in this family, with varying effects (see Table 1).
In a similar fashion to ABO blood groups, in which natural
antibodies are made to speciﬁcities that individuals lack,
humans produce anti-aGal antibodies as a consequence of
nonfunctional, or nontranslated enzymes. The evolutionary
event that led to selection of the aGal-ve phenotype in
humans is not clear, but selective pressure of the aGalþve
protozoan parasites has been postulated [20].
It is well known that the presence of the Gala(1,3)Gal
xenoepitope, synthesized by a1,3galactosyltransferase
(a1,3GT), causes hyperacute rejection of donor organs in
pig-to-human xenotransplantation [21]. To avoid this prob-
lem, the a1,3GT gene has recently been deleted in pigs [22].
However, there is still low-level expression of Gala(1,3)Gal
[23], presumably synthesized by iGb3S. Thus, organs from
GT
 /  pigs transplanted into humans may still potentially be
subject to rejection by human natural antibodies to
Gala(1,3)Gal in the form of iGb3. The study from Zhou and
colleagues [7] provided data suggesting that this is unlikely to
pose an immediate problem, because they showed that
human anti-Gal antibodies did not react with iGb3, presum-
ably because it was a self-ligand that caused deletion of iGb3-
reactive lymphocytes in humans. Thus, although there is
clearly a signiﬁcant level of controversy surrounding iGb3,
the fact remains that there are compelling results both for
and against a role for iGb3 in NKT cell development. For the
sake of understanding the factors that regulate this process,
as well as whether iGb3 poses an additional problem for
xenotransplantion, further studies are required to resolve
this issue.
We recently characterized the mouse iGb3S cDNA [24] that
encodes the enzyme that synthesizes the Gala(1,3)Gal xen-
oepitope on iGb3 by catalysing the transfer of donor sugar
from UDP-Gal in an a 1,3 linkage to its acceptor molecule
Galb(1,4)Glc-ceramide [25]. This reaction is the ﬁrst step in
the isoglobo-series pathway, which also results in the
generation of iGb4 and isoForssman glycolipids (Figure 1).
Here, we have examined iGb3S expression and functional
Table 1. Characteristics of Human a1,3Gal/GalNAc (Family 6) Glycosyltransferases
Glycosyltransferase Mutation Transcribed Translated Enzymatic
Function
Note Reference
a1,3galactosyltransferase Multiple point mutations and deletions Yes No No Two pseudogenes in genome [44,45]
A blood group transferase Point mutation amino acid change Yes Yes No O blood group phenotype [46]
Point mutation frame shift Yes ? No O blood group phenotype [47]
Forssman synthase Multiple point mutations multiple
amino acid changes
Yes Yes No [27]
doi:10.1371/journal.pbio.0060172.t001
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Humans Do Not Produce iGb3
Author Summary
Identification of endogenous antigens that regulate natural killer T
(NKT) cell development and function is a major goal in immunology.
Originally the glycosphingolipid, iGb3, was suggested to be the
main endogenous ligand in both mice and humans. However,
recent studies have challenged this hypothesis. From a xenotrans-
plantation (animal to human transplants) perspective, iGb3 expres-
sion is also important as it represents another form of the major
xenoantigen Gala(1,3)Gal. In this study, we assessed whether
humans expressed a functional iGb3 synthase (iGb3S), the enzyme
responsible for lipid synthesis. We showed that spliced iGb3S mRNA
was not detected in any human tissue analysed. Furthermore,
chimeric molecules composed of the catalytic domain of human
iGb3S were unable to synthesize iGb3 lipid, due to at least one
amino acid substitution. We also demonstrated that purified human
anti-Gal antibodies bound iGb3 lipid and mediated destruction of
cells transfected to express iGb3. A nonfunctional iGb3S in humans
has two major consequences: (1) iGb3 is unlikely to be a natural
human NKT ligand and (2) natural human anti-Gal antibodies in
human serum could react with iGb3 on the surface of organs from
pigs, marking these tissues for immunological destruction.potential in human tissues. Moreover, to assess whether iGb3
might represent a xenoantigen that remains in a1,3GT
knockout pigs, we investigated whether iGb3 glycolipid is
recognized by natural human anti-Gal antibodies present in
normal human serum, and we also determined whether cells
expressing this glycolipid on the cell surface are readily
targeted for complement-mediated lysis.
Results
Spliced iGb3S mRNA Is Not Detected in Any Human Tissue
Analysed
Several lines of evidence from our studies of the
Gala(1,3)Gal epitope suggest that iGb3S is not expressed in
humans. In contrast to both rat and mouse, in which the
iGb3S gene is transcribed and the RNA processed [24,25],
analysis of a human multiple tissue northern blot did not
detect iGb3S mRNA (unpublished data). Furthermore, anti-
Gal monoclonal antibodies (mAbs) that detect both rat and
mouse iGb3 on tissues and cell lines do not react with a range
of both normal and malignant human tissues and cell lines
[24] (and our unpublished data). To examine expression of
iGb3S mRNA in greater detail, reverse-transcription PCR
(RT-PCR) was used to analyse several human tissues.
Oligonucleotide primers for these experiments (Table S1)
were designed based on the exon arrangement of the human
iGb3S gene, established by the analysis of Genbank DNA
sequences. RNA from heart, kidney, spleen, lung, and thymus
(the latter two tissues express iGb3S in both rat and mouse)
generated a product of the correct size (;550 bp) with
forward and reverse primers within exon ﬁve (unpublished
data). A product was also obtained from cDNA from human
dendritic cells (Figure 2B, lane 6). Some products were
conﬁrmed as human iGb3S by direct sequencing (unpub-
lished data). However, generation of products within an exon
may be due to genomic DNA or heteronuclear RNA;
therefore, ampliﬁcation across exon boundaries is required
to show the presence of mRNA. We have previously shown
Figure 1. Lacosylceramide (Lac-Cer) Is the Starting Material for the Synthesis of Glycolipids via Two Distinct Pathways, the Isoglobo and Globo Series
The major difference between the two pathways is that in the isoglobo series, iGb3S transfers an aGal in an a1,3 linkage, whereas in the globo series,
Gb3S transfers an aGal in an a1,4 linkage. The relevant enzymes that catalyse the reactions to generate the different glycolipids are shown in italics. The
antibodies that are used to detect these products are shown in bold.
doi:10.1371/journal.pbio.0060172.g001
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Humans Do Not Produce iGb3that iGb3S mRNA can be successfully used as a template for
cross-exon RT-PCR from mouse RNA [24]. Despite exhaustive
attempts (at least 50 times) to amplify human iGb3S using a
combination of primers spanning all ﬁve exons in different
tissues (Figure 2A), products were either not obtained from
human template or the size of several of the PCR products
corresponded to that expected from genomic DNA rather
than spliced mRNA. The data shown are the ampliﬁcation
from dendritic cells (Figure 2B); however, similar results were
also obtained from all tissues examined. Primers across exon
1 to 3, exons 1 to 4, and exons 2 to 4 yielded products
expected from ampliﬁcation of genomic DNA rather than
spliced RNA (lanes 1, 2, and 4, respectively, Figure 2B and
Table S2). The products observed in lanes 6 and 7 are within a
single exon and could represent either genomic or mRNA
products as there is no splicing over this region of the iGb3S
gene. Despite using numerous primer combinations, includ-
ing forward primers from exons 2, 3, or 4 with a reverse
primer from exon 5 (Figure 2C), we were unable to detect any
products of the correct size to suggest spliced iGb3S mRNA in
any human tissue examined (Figure 2D), even when a high
cycle number (up to 40) was used (unpublished data). As
expected, products were not observed when template was
omitted.
Chimeric Human iGb3S Molecules Do Not Synthesize the
Gala(1,3)Gal Xenoepitope
From our experience, mouse iGb3S mRNA is expressed at
low levels and is difﬁcult to amplify. Therefore, our inability
to detect human iGb3S mRNA was not conclusive evidence
that it was absent. Transfection of CHOP cells with mouse
iGb3S cDNA results in high level expression of its product
Gala(1,3)Gal [24]. We used the same approach to determine
whether humans express functional iGb3S. In vitro functional
studies indicate that the catalytic domain of iGb3S (which
represents 75% of the entire molecule) is encoded by two
exons, a small exon (exon 4) and a larger one (exon 5)
encoding the major part of the functional domain [26].
Soluble forms of the truncated catalytic domain of several
members of the glycosyltransferase family have been shown to
be enzymatically active. Using splice overlap extension PCR,
we initially generated a chimeric molecule in which exon 5 of
the functional rat iGb3S was substituted with that of the
human iGb3S homolog (generated from human genomic
DNA) (Figure 3A and Table S3). The other rat exons encode
the cytoplasmic tail, transmembrane domain, and stalk that
anchors the molecule in the lipid bilayer. This approach of
exchanging catalytic domains to examine function has been
successfully used with Forssman synthetase, another member
of this glycosyltransferase family [27]. The ability of this
chimeric rat/human(exon5)-iGb3S molecule to synthesize
Gala(1,3)Gal was determined by analysis of transfected CHOP
cells. As expected, cells transfected with DNA encoding rat
iGb3S displayed strong cell surface expression of the
Gala(1,3)Gal epitope on glycolipid as determined by binding
of the monoclonal antibody 15.101 [28] and human anti-Gal
immunoglobulin (Ig) puriﬁed from normal human serum
(Figure 3B). The 15.101 mAb has been shown to bind
preferentially to Gala(1,3)Gal on iGb3 lipid [28]. The chimeric
molecule containing the majority of the catalytic domain of
human iGb3S (rat/human(exon5)-iGb3S) was unable to
synthesise the Gala(1,3)Gal epitope as staining was not
Figure 2. Spliced iGb3S mRNA Is Not Detected in Human Tissues
(A) Schematic representation of the exon arrangement of human iGb3
synthase. Numbers (1–7) in the left-hand column denote the different
primer combinations used in PCR analysis. Arrows define both primer
direction and specific binding exons.
(B) PCR products generated from dendritic cell cDNA template using the
primer combinations described above. Numbers on the left are size
markers (kilobases).
(C) Schematic representation of the exon arrangement of human iGb3S.
Numbers (1–4) in the left-hand column denote the different primer
combinations used in PCR analysis. Arrows define both primer direction
and specific binding exons.
(D) PCR products generated from dendritic cell cDNA template using the
primer combinations described above. Numbers on the left are size
markers (kilobases). Using these and other primer combinations, these
PCR experiments were repeated several times.
doi:10.1371/journal.pbio.0060172.g002
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Humans Do Not Produce iGb3Figure 3. Chimeric Rat/Human-iGb3S Molecules Are Unable to Synthesize Gala(1,3)Gal or IsoForssman
(A) Schematic diagram of rat iGb3S, chimeric rat/human(exon5)-iGb3S, and rat/human(exon4,5)-iGb3S. Rat exons are shaded grey; substituted human
exons are unshaded.
(B) Cell surface Gala(1,3)Gal expression after transfection with DNA encoding chimeric molecules (rat/human(exon5)-iGb3S and rat/human(exon4,5)-
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Humans Do Not Produce iGb3observed with 15.101 or human anti-Gal Ig (Figure 3B). A
second chimeric molecule comprising the entire human
catalytic domain, exon 4 together with exon 5 (rat/human(e-
xon4,5)-iGb3S), was also unable to synthesize Gala(1,3)Gal
(Figure 3B). Data from several other mAbs and Bandeiraea
simplicifolia IB4 lectin that bind the Gala(1,3)Gal epitope
(Figure S1) support the conclusion that the human iGb3S
catalytic domain is not functional. Detection of the FLAG
epitope in both chimeric enzymes conﬁrmed that the absence
of Gala(1,3)Gal synthesis was not due to impaired translation
or expression (Figure S2A). As glycosyltransferases are
integral membrane proteins of the Golgi complex where
oligosaccharides are synthesized, perinuclear staining (Golgi-
like) conﬁrmed correct trafﬁcking of the chimeric enzymes
(Figure S2B). Staining was not observed with cells transfected
with vector alone.
The Absence of iGb3 Staining Is Not Due to Antibody
Inaccessibility or It Acting as a Precursor to Generate
IsoForssman
To explore the unlikely possibility that iGb3 staining was
not observed due to antibody inaccessibility, an alternative
detection method was used. Synthesis of iGb3 is the initial
step for the formation of the isoglobo-series glycolipid
pathway, and iGb3 is the precursor to iGb4 and, ultimately,
isoForssman [25] (see Figure 1). To examine whether iGb3 was
synthesized, a complementation assay in CHOP cells, which
lack both iGb3S and Forssman synthetase (FS), was used to
determine whether coexpression of chimeric iGb3S with FS
results in expression of isoForssman glycolipid. As expected,
cells transfected with FS alone did not stain for isoForssman
(unpublished data), whereas cells transfected with both rat
iGb3S and FS were positive for isoForssman (Figure 3C).
Expression of Gala(1,3)Gal was conﬁrmed by 15.101 binding.
Cells cotransfected with either of the chimeric molecules (rat/
human (Exon5)-iGb3S or rat/human (Exon4,5)-iGb3S) and FS
did not show any detectable isoForssman staining (Figure 3C).
As expected, no Gala(1,3)Gal was observed following staining
with 15.101. Thus, the human catalytic domain appears to be
incapable of generating detectable iGb3 and does not initiate
the downstream synthesis of the iGb4 structure required for
FS to function.
Pro 187 and Asn 252 in Human iGb3S Affect Enzymatic
Function
Using site-directed mutagenesis, we analysed which amino
acid(s) contributed to the loss of function we observed in
human iGb3S. Despite an overall similarity of approximately
72%, there are 77 differences within the catalytic domain of
the functional rat iGb3S and nonfunctional human iGb3S,
any of which, either alone or in combination, may be involved
in the loss of function observed with human iGb3S. The
targeted residues were selected by comparison of the aligned
amino acid sequences of the iGb3S catalytic domains (exon 4
and 5 encoded) of species known to synthesize iGb3 (rat,
mouse, and dog) with that of human. To identify more precise
candidates, amino acids were excluded: (1) if the human
amino acid was identical to either the mouse or dog, (2) the
amino acid residue was different in all four species, or (3) the
substitution was with an homologous amino acid. Four of
these amino acids in rat exon 5 were selected in these initial
studies and mutated to their human equivalent (Figure 4A).
The single isolated substitution of rat Y252N resulted in the
complete elimination of Gala(1,3)Gal staining (Figure 4B),
showing that this asparagine in human iGb3S is sufﬁcient to
ablate enzymatic function. Rat L187P showed a signiﬁcant
reduction (typically 70%–95%) in Gala(1,3)Gal staining,
whereas both the rat A221S and rat E280A substitutions
showed strong Gala(1,3)Gal expression that was comparable
with that observed following transfection with rat iGb3S
(Figure 4B). As expected, a complementation assay with FS
resulted in strong isoForssman staining with both rat A221S
and rat E280A substitutions (Figure 4C). A similar high level of
isoForssman staining was also observed with the rat L187P
substitution, despite there being minimal Gala(1,3)Gal ex-
pression, thus demonstrating the sensitivity of this method.
IsoForssman staining was not observed with cells cotrans-
fected with rat Y252N (Figure 4C).
Human iGb3S Is Inactive because of Multiple Mutations
It is possible that the Y252N and L187P substitutions are not
the only ones in humans that inﬂuence function. This was
examined by reverse mutation of the nonfunctional chimeric
rat/human(exon 5)-iGb3S to their rat equivalents with either
point mutation alone (i.e., P187Lo rN 252Y), or in combination
(P187LþN252Y). A gain of function would suggest these are the
primary residues involved in determining whether the trans-
ferase is functional. Staining with mAb 15.101 showed no
Gala(1,3)Gal expression following transfection of CHOP cells
with either the single or combined reverse-mutated chimeric
cDNA molecules (Figure 5). The implications of these data are
that human iGb3S must have multiple mutations that have
resulted in its inactivation. Typical strong Gala(1,3)Gal
expression was observed with cells transfected with rat iGb3S.
Purified Human Anti-Gal Antibodies Bind iGb3 Lipid
High-performance thin layer chromatography data from
Zhou et al [7] suggested natural mixed human serum
antibodies did not recognize iGb3, suggesting that iGb3-
reactive B cells had been deleted from the human repertoire,
further evidence that iGb3 lipid is present in humans. To test
this ourselves, we used a lipid ELISA, and by this approach,
demonstrated clear binding of both natural human anti-
Gala(1,3)Gal antibodies and the mAb 15.101 to puriﬁed iGb3
lipid over several antibody dilutions (Figure 6A). Binding was
not observed with either anti-CD17 (lactosylceramide) or
anti-CD77 (Gb3) mAbs. Furthermore, as a speciﬁcity control,
treatment of iGb3 lipid with a-galactosidase, which speciﬁ-
cally removes the terminal a(1,3)Gal moiety, resulted in a
signiﬁcant inhibition (up to 60%) of binding by natural
human anti-Gala(1,3)Gal antibodies (Figure 6B), yet had no
effect on anti-CD17 binding to lactosylceramide (no aGal
iGb3S) following staining with either the anti-Gala(1,3)Gal mAb 15.101 or natural human anti-Gal antibodies. The data are representative of five
experiments.
(C) IsoForssman and Gala(1,3)Gal expression following cotransfection with DNA encoding rat iGb3S or the chimeric molecules (rat/human(exon5)-iGb3S
and rat/human(exon4,5)-iGb3S) and Forssman synthetase (FS). Cells were stained with either the anti-Forssman mAb or the Gala(1,3)Gal mAb 15.101.
The data are representative of two experiments. Background staining with secondary antibody alone is shown by the dotted histograms in each panel.
doi:10.1371/journal.pbio.0060172.g003
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Humans Do Not Produce iGb3Figure 4. A Single Substitution in Rat iGb3S Completely Eliminates Gala(1,3)Gal Staining
(A) Diagram, based on the crystal structure of rat iGb3S, showing the structure of exons 4 and 5 with the relative positions of the rat to human amino
acid substitutions. The arrows represent beta sheets and the cylinders alpha helices.
(B) Expression of Gala(1,3)Gal following staining with the anti-Gala(1,3)Gal mAb 15.101 of the rat to human point mutants (L187P, A221S, Y252N, and
E280A). Background staining with secondary antibody alone is shown by the dotted histograms in each panel. The data are representative of five
experiments.
(C). IsoForssman expression following cotransfection of Forssman synthetase (FS) with DNA encoding the rat to human point mutants L187P, A221S,
Y252N, and E280A. Cells were stained with the anti-Forssman mAb. The data are representative of three experiments. Background staining with
secondary antibody alone is shown by the dotted histograms in each panel.
doi:10.1371/journal.pbio.0060172.g004
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Humans Do Not Produce iGb3moiety) in a parallel assay. Antibody speciﬁcity was further
demonstrated by the lack of binding of natural human anti-
Gala(1,3)Gal antibodies to either Gb3 (Figure 6C) or
lactosylceramide (Figure 6D). However, as expected speciﬁc
binding of both anti-CD77 and anti-CD17 mAbs (used at the
same dilutions as in Figure 6A) were observed (Figure 6C and
6D, respectively).
Human Cells Expressing iGb3 Undergo Complement-
Mediated Lysis
A key question that remains to be answered is, if human
cells were to express iGb3, would they be susceptible to
antibody-dependent complement-mediated lysis due to nat-
ural human anti-aGal antibodies present in normal human
serum (NHS)? In contrast to nontransfected human cells
(aGal
 ve) that do not undergo lysis with NHS, human cells
expressing iGb3 (aGal
þve) were lysed by NHS (in the presence
of rabbit complement) in a dose-dependent manner (Figure
7A). Removal of anti-aGal antibodies from NHS by absorp-
tion with Gala(1,3)Gal coupled to glass beads abolished lysis
to background levels (Figure 7A). However, lysis was not
affected by NHS absorption with uncoupled glass beads
(unpublished data). Furthermore, lysis of human cells
expressing iGb3 was re-established when anti-aGal IgG
antibodies were puriﬁed from NHS and used in the
cytotoxicity assay (Figure 7A). In addition, this activity could
be removed by absorption with Gala(1,3)Gal coupled to glass
beads (unpublished data). Inhibition experiments veriﬁed
that Gala(1,3)Gal is the epitope that the antibodies recognise,
as a signiﬁcant dose-dependent reduction in lysis was
observed by preincubation of both NHS and anti-aGal IgG
antibodies with Gala(1,3)Gal disaccharide (Figure 7B). No
inhibition was observed when lactose (Galb(1,4)Glc) was used
(Figure 7B).
Discussion
Glycolipids represent one of the last molecular frontiers in
immunological recognition. Whereas glycolipids are known
to be synthesized in the Golgi and are typically expressed on
the cell surface, the exact transport pathway(s) for newly
synthesized glycolipids is not well deﬁned. However, it is
assumed to be similar to glycoproteins and involve vesicular
ﬂow from the endoplasmic reticulum through the Golgi
complex to the plasma membrane. Glycolipids, particularly
exogenous glycolipids, can localize to lysosomal compart-
ments via endocytosis. Similarly, our knowledge of how
glycolipids control immune responses and the context in
which they are presented by CD1d and recognized by NKT
cells is also still very limited. Since the glycolipid, a-GalCer,
was originally shown to potently stimulate NKT cells in a
CD1d-dependent manner, there has been an enormous effort
to identify other ligands. Several classes of natural CD1d-
binding ligands for NKT cells have been identiﬁed, including
microbial-derived a-linked glycosphingolipids from the non-
pathogenic Sphingomonas bacteria and phosphatidylinositol
mannoside from Mycobacteria (reviewed in [29]). Recently, a
diacylglycerol glycolipid from Borrelia burgdorferi, a human
pathogen responsible for Lyme disease, was shown to directly
stimulate both human and mouse NKT cells [30]. Although
these ligands are all candidates for NKT cell recognition of
non-self, none of these are present in normal mammalian
cells.
The main candidate self glycolipid-antigen is iGb3. The
original collective data, primarily based on the use of b-
hexosaminidase-B–deﬁcient mice that are incapable of
degrading iGb4 into iGb3 in lysosomes, supported the claim
that iGb3 lipid was a principle endogenous ligand for Va14
NKT cells in mice and, albeit indirectly, in humans [7,12,31].
The interpretation of data using b-hexosaminidase-B–deﬁ-
cient mice was contested by Gadola et al. [14], where it was
argued that these mice have a generalised lysosomal storage
disease that indirectly impaired CD1d loading in lysosomes.
Their interpretation was that it was the accumulation of
glycolipids in lysosomes, rather than the lack of iGb3, that
abrogated NKT cell development. Some of the data in this
paper [14] simply conﬂicted with that of the earlier study of
b-hexosaminidase-B–deﬁcient mice [7], making it difﬁcult to
determine which interpretation was correct [14]. Similar
suggestions were raised in an independent study of mutations
leading to lysosomal storage diseases [18]. Recently, Porubsky
et al. and Speak et al. [15,16] failed to detect iGb3 in mouse
and human thymus using a biochemical approach. Further-
more, Porubsky et al. [15] reported normal development and
function of invariant NKT (iNKT) cells in iGb3S
 /  mice.
Figure 5. Human iGb3S Appears to Be Inactive because of Multiple
Mutations
Gala(1,3)Gal expression of the reverse human to rat single (P187L, N252Y)
or combined point mutations (P187LþN252Y). Background staining with
secondary antibody alone is shown by the dotted histograms in each
panel. The data are representative of three experiments.
doi:10.1371/journal.pbio.0060172.g005
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Humans Do Not Produce iGb3Although the lack of biochemical evidence for iGb3 in thymus
might simply be an issue of insufﬁcient sensitivity, the results
from the iGb3S
 /  mice more strongly challenge the signiﬁ-
cance of iGb3 in mouse NKT cell development. There is no
easy interpretation that incorporates and integrates the
ﬁndings from the studies for, and against, a role for iGb3 in
mouse NKT cell development. In our opinion, this represents
one of the most important and controversial issues in the
NKT cell ﬁeld that requires additional input from independ-
ent research groups.
In humans, synthetically derived iGb3 can stimulate human
NKT cells to proliferate and produce cytokines [7,8,32] and
recognition of human dendritic cell self-antigen can be
blocked by IB4 lectin [7]. However, direct biochemical
evidence to show that human iGb3 is an endogenous NKT
cell ligand has been lacking. Although iGb3 was not detected
in human thymus or human dendritic cells using a high-
performance liquid chromatography (HPLC) assay, this assay
had a detection limit of 1% iGb3 to 99% Gb3, which does not
exclude the presence of iGb3 at low but still biologically
signiﬁcant levels [16]. Indeed, during review of this manu-
script, two publications from Li et al., claimed to be able to
discriminate iGb3 from Gb3 (in artiﬁcial mixtures and from
rat cells) and identiﬁed iGb4 from human paediatric thymi,
using electrospray ionisation-ion trap mass spectrometry
[33,34]. Although these analyses are at odds with our own,
they have yet to conclusively demonstrate immunologically
signiﬁcant levels of iGb3 in human tissue. Speciﬁcally, the
formal possibility remains that the minor MS
n mass spectral
signature for iGb4 detected in these studies is derived from
related tetraglycosylceramides, as acknowledged by these
investigators. Alternatively, the very low levels of iGb4
detected in these analyses may be derived from dietary
sources and distributed throughout the body via lipoprotein
particles.
The presence or absence of iGb3 in humans has potential
major implications for xenotransplantation. If humans
express iGb3S, iGb3 lipid present on transplanted pig tissues
will not be ‘‘seen’’ as foreign and therefore would not
represent a drawback for xenotransplantation. However, as
humans do not express functional iGb3S (reported herein),
then the presence of lipid-linked Gala(1,3)Gal in pigs,
synthesized by iGb3S, may pose a serious risk to successful
xenotransplantation, even when using a1,3GT knockout pigs
as donors (which were speciﬁcally generated to eliminate
Gala(1,3)Gal epitopes for xenotransplantation purposes).
What are the implications of this in a transplant setting?
Currently, we know that expression of iGb3 does not mediate
hyperacute rejection of pig tissues transplanted into baboons
[35,36]. However, human serum has at least a 4-fold higher
level of natural anti-Gala(1,3)Gal antibodies (;1% of human
Figure 6. Purified Human Anti-Gala(1,3)Gal Antibodies Bind iGb3 Lipid
(A) Doubling dilutions of natural purified human anti-Gala(1,3)Gal
antibodies (0.49 mg/ml) (filled squares) (diluted 1/10) and anti-
Gala(1,3)Gal mAb 15.101 supernatant (open circles) (diluted 1/2) binding
to plate-bound iGb3 lipid. Background binding with anti-CD17 ascites
(lactosylceramide) (diluted 1/40) and purified anti-CD77 (Gb3: 0.15 mg/
ml) (diluted 1/50) is shown with open squares and closed circles,
respectively.
(B) Percent inhibition in binding of natural human anti-Gala(1,3)Gal
antibodies to iGb3 lipid following a-galactosidase treatment at the
dilutions shown. Unfilled columns represent the binding of anti-CD17 to
plate-bound lactosylceramide after a-galactosidase treatment.
(C and D) Binding of natural purified human anti-Gala(1,3)Gal antibodies
(filled squares), anti-CD17 ascites (open squares), and purified anti-CD77
(closed circles) to either plate-bound Gb3 (C) or lactosylceramide (D).
The data are representative of two experiments.
doi:10.1371/journal.pbio.0060172.g006
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Humans Do Not Produce iGb3IgG) than other primates [37], so this may not directly
represent the human situation. Furthermore, iGb3 expression
in pigs may have more serious consequences in the later
phases of graft rejection. Firstly, changes in the afﬁnity/
avidity of the elicited antibodies may cause tissue damage by
complement ﬁxation. It is clear that the level of anti-
Gala(1,3)Gal antibody is critical for the speed of rejection
in experimental models [38]. Alternatively, elicited anti-
Gala(1,3)Gal antibodies may contribute to the acute vascular
rejection observed when hyperacute rejection is eliminated,
such as in knockout pig-to-primate transplants, by activation
of endothelial cells via cross-linking of the lipid itself.
Pathological features similar to acute vascular rejection are
seen in humans when the Gb3 lipid (closely related to iGb3) is
cross-linked by bacterial toxins [39]. Secondly, because iGb3
activates human NKT cells [7,32] (in which synthetic, puriﬁed.
and enzymatically derived iGb3 were all tested), consequently
the expression of iGb3 on pig cells could lead to NKT cell
activation resulting in destruction of the xenograft. Further-
more, our data clearly show that the anti-Gal antibodies in
NHS can lyse iGb3 expressing cells (Figure 7) and therefore
any remaining iGb3 on pig cells may be a target for antibody-
mediated destruction. Whereas it is clear that the use of heavy
immunosuppression can control the later phases of xenograft
rejection, the major advantage of xenotransplantation over
allotransplantation is the ability to genetically modify the
donor. The ultimate goal is to engineer a donor pig such that
minimal, or indeed no immunosuppression is required for
long-term graft survival. It is likely that genetic modiﬁcation
of pigs may be required to eliminate any effects of iGb3. Only
at that stage will other obstacles be revealed. Thus, in formally
demonstrating the lack of functional iGb3S in humans, this
study alerts transplantation immunologists to a previously
unrecognised risk associated with expression of iGb3 glyco-
lipid on a1,3GT knockout pig tissues. Expression of this
glycolipid could act as a secondary source of Gala(1,3)Gal
xeno-antigen capable of binding natural human anti-Gal
antibodies present in normal human serum and marking
these cells for destruction by complement mediated lysis.
In a perspectives article, Godfrey, Pellicci, and Smyth [40]
asked whether the search for the elusive NKT cell antigen is
over. In mice, in view of several recent publications [14–16],
the possible existence of NKT cell-selecting ligands other
than iGb3 remains an important consideration [17]. It had
generally been assumed that experimental data obtained
from mice would be directly relevant to humans, and Zhou et
al. [7] provided indirect evidence that iGb3 is also a self-
ligand for human NKT cells. However, our new data
demonstrate that there appears to be critical differences
between the two systems, and suggests that we are a long way
from calling off the search for NKT cell-selecting antigens in
humans. This remains one of the most important objectives
in the ﬁeld, and will ultimately lead to a better understanding
of the factors that regulate NKT cell development and
function in health, and in developing novel therapies for the
treatment of disease.
Materials and Methods
Genomic database searching. The human genomic iGb3S sequence
was obtained from the National Center for Biotechnology Informa-
tion Web site (http://www.ncbi.nlm.nih.gov) and searching the human
genomic database. The nucleotide sequence of the gene A3GALT2
(accession number NT 032977) was used, with the exon/intron
boundaries for the human iGb3S gene as listed with the sequence.
PCR. We were unable to clone human iGb3S from total RNA from
adult human tissues (heart, lung, kidney, spleen, and thymus)
(Stratagene) or cDNA from dendritic cells using the TITANIUM
One-Step RT-PCR Kit (Clontech) with a series of degenerate primers
(Tables S1 and S2). The chimeric rat/human molecules included the
exchange of rat exon 5 (rat/human(exon5)-iGb3S) and rat exons 4 and
5 (rat/human(exon4,5)-iGb3S) with the equivalent human exon(s). The
Figure 7. Complement-Mediated Lysis of Human Cells Expressing iGb3
(A) Percent lysis of human cells expressing iGb3 following addition of
normal human serum (filled circles), purified anti-aGal IgG antibodies
(filled squares) and NHS absorbed on Gal column (open circles) and
nontransfected human cells following addition of NHS (open squares).
Serum dilution is shown on the horizontal axis. Data are representative of
three experiments.
(B) Percent inhibition of lysis of human cells expressing iGb3 by
preincubation of NHS with Gala(1,3)Gal disaccharide (closed circles) or
lactose (open circles) or purified anti-aGal IgG antibodies with
Gala(1,3)Gal disaccharide (closed squares) or lactose (open squares).
Inhibitor dilution is shown on the horizontal axis. Data are representative
of two experiments.
doi:10.1371/journal.pbio.0060172.g007
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PCR. The speciﬁc primer combinations used are shown in Table S3.
The single amino acid substitutions in rat iGb3S (L187P, A221S, Y252N,
and E280A) and the reverse mutations in rat/human(exon5)-iGb3S
(P187L, N252Y, and the combined P187LþN252Y) were introduced using
the QuikChange site-directed mutagenesis kit (Stratagene) (Table S4).
Sequence ﬁdelity, orientation of the insert, and presence of the
desired mutation(s) were conﬁrmed by DNA sequencing (Big Dye 3.1;
PE-Applied Biosystems).
Cell culture, transfection, and antibodies. CHOP cells (Chinese
Hamster Ovary cells transformed with Polyoma Large T antigen) [41]
and E293 cells (human kidney ﬁbroblasts) were cultured in DMEM
(CSL) supplemented with 10% FCS overnight at 37 8C. Transfections
were with LipofectAMINE Plus (Life Technologies) as recommended
by the manufacturer. Cells were examined after 48 h for either cell
surface or intracellular expression of Gala(1,3)Gal using puriﬁed
natural human anti-Gal antibodies (0.49 mg/ml), and the anti-
Gala(1,3)Gal mAbs 15.101, 22.121, 24.7, 25.2, and 8.17 (supernatants)
[24,42] and Bandeiraea simplicifolia IB4 lectin. Expression of the FLAG
epitope was revealed by staining with the anti FLAG M2 mAb (Sigma).
Expression of IsoForssman glycolipid was revealed using an anti-
Forssman mAb, FOM-1 (BMA Biomedicals). Expression of lactosyl-
ceramide and Gb3 were revealed with anti-CD17 (ascites) and
puriﬁed anti-CD77 (0.15 mg/ml) mAbs, respectively (Pharmingen).
Antibodies were detected with FITC-labelled sheep anti-mouse or
human IgG (Dako) or HRP conjugate Sheep anti-human Ig (Silenus)
and rabbit anti-mouse Ig (Dako), and analysed either by ﬂuorescence
microscopy, ﬂow cytometry (Becton Dickinson FACS Canto II), or
lipid ELISA.
Lipid ELISA and enzyme digestion. Porcine lactosylceramide
(Calbiochem) and iGb3 (Alexis Biochemicals) were dissolved in
methanol at 1 mg/ml and stored at 20 8C. The ELISA was performed
in 96-well Maxisorb plates (Nunc). Lipids were diluted in n-hexane
and used at 500-ng/well, incubated for 1 h in a fume hood to dry;
plates were then blocked with 3% BSA/PBS for 2 h and washed 31
with PBS. Primary antibodies, diluted in blocking buffer, were added
and incubated for 1 h. After washing 35 with PBS, secondary
antibodies, diluted in blocking buffer, were added and incubated for
1 h before washing 38 with PBS. All incubations were carried out at
room temperature (RT) on a rocking platform. TMB peroxidase
substrate (KPL) was used to develop the plate. Colour development
was stopped with 0.18 M H2SO4 and quantitated at an optical density
at 405 nm (OD405nm) on an ELISA plate reader. For the enzyme
digestion, a-galactosidase (Sigma-Aldrich) was diluted in 0.1 M
citrate/phosphate buffer (pH 6) and incubated with the lipids
overnight at RT, after which an ELISA was performed as described
above.
Complement-mediated lysis. Human E293 cells expressing rat iGb3
[28] were tested for lysis with rabbit complement and normal human
sera (NHS, pooled from ten healthy individuals and heat inactivated)
or puriﬁed human anti-Gal IgG antibodies (prepared by fractionation
of the NHS pool on a Protein G Sepharose column (Pharmacia)
followed by afﬁnity chromatography on Gala(1,3)Gal-coupled macro-
porous glass beads (Syntesome) as described previously [43]. In brief,
50 ll of antibody at doubling dilutions were added to 2.5 3 10
5 cells
per well in round-bottomed 96-well plates (Greiner), resuspended,
and incubated on ice for 30 min. After two washes, 50 ll of rabbit
complement, at an appropriate dilution, was added to the cell pellet,
resuspended, and incubated at 37 8C for 30 min (NHS) or 60 min
(puriﬁed anti-Gal IgG). Cells were pelleted and resuspended in 400 ll
of DMEM/0.5% BSA containing 1 lg/ml propidium iodide (PI; Sigma)
and analysed by ﬂow cytometry. Percentage lysis (cytotoxicity) was
determined by analysis of 10,000 cells.
The importance of anti-Gal antibodies for lysis was determined by
serum absorption and carbohydrate inhibition: (1) Absorption; 200 ll
of NHS or human anti-Gal IgG was added to an equal volume of
Gala(1,3)Gal-coupled macroporous glass beads or non-coupled beads
(control) at 4 8C for 30 min; the beads were removed by
centrifugation and the absorption step repeated with another aliquot
of beads. (2) Carbohydrate inhibition; 25 ll of 20 mM Gala(1,3)Gal
disaccharide or lactose (control) was serially diluted and mixed with
an equal volume of NHS or human anti-Gal IgG at an appropriate
dilution (two dilutions less than the 50% titre of the antibody) and
incubated at 4 8C for 16 h. After both of these treatments, the sera
were analysed for complement-mediated lysis.
Supporting Information
Figure S1. Cell Surface Staining of Transfected Cells Using
Monoclonal Antibodies
Shows Gala(1,3)Gal expression on cells expressing rat iGb3S, rat/
human(Exon5)-iGb3S, or rat/human(Exon4,5)-iGb3S following stain-
ing with a panel of the anti-Gala(1,3)Gal mAbs 22.121, 24.7, 25.2, or
8.17 and the IB4 lectin. Background staining with secondary antibody
alone is shown by the dotted histograms in each of the 16 panels. The
data are representative of two experiments.
Found at doi:10.1371/journal.pbio.0060172.sg001 (69 KB PDF).
Figure S2. Chimeric Protein Expression after Transfection
(A) shows a western blot showing anti-FLAG staining of lysates from
mock-transfected CHOP cells (lane 1), cells transfected with rat/
human(Exon4,5)-iGb3S (lane 2), or rat/human(Exon5)-iGb3S (lane 3).
The arrow represents the expected size of the chimeric proteins (40
kD) observed in lanes 2 and 3. The darker, lower band observed in all
wells is nonspeciﬁc.
(B) Fluorescence microscopy showing perinuclear (Golgi-like) stain-
ing of rat iGb3S (panel 1), rat/human(Exon4,5)-iGb3S (panel 2), and
rat/human(Exon5)-iGb3S (panel 3).
Found at doi:10.1371/journal.pbio.0060172.sg002 (128 KB PDF).
Table S1. Primers Used in PCR Analysis of Human Tissues and in the
Generation of Chimeric Rat/Human iGb3S
Found at doi:10.1371/journal.pbio.0060172.st001 (58 KB DOC).
Table S2. PCR Primer Combinations Used to Analyse Dendritic Cell
(DC) cDNA
The ﬁrst primer in each of the combinations is the forward primer.
Predicted genomic sizes were calculated using the original Genbank
data ﬁle NT004511.16.
Found at doi:10.1371/journal.pbio.0060172.st002 (31 KB DOC).
Table S3. Primer Combinations Used in Generating Chimeric Rat/
Human-iGb3S-Flag cDNAs
Found at doi:10.1371/journal.pbio.0060172.st003 (29 KB DOC).
Table S4. Primers for Generating Speciﬁc Amino Acid Changes in
Rat iGb3S and Chimeric Rat/Human(exon5)-iGb3S
Found at doi:10.1371/journal.pbio.0060172.st004 (39 KB DOC).
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